Secondary Logo

Journal Logo

It's Been Fun and Productive Too

Asbell, Penny A., M.D., F.A.C.S., M.B.A., F.A.R.V.O.

doi: 10.1097/ICL.0000000000000600
Editorial
Free

Department of Ophthalmology, Hamilton Eye Institute, University of Tennessee Health Science Center, Memphis, TN.

The author has no funding or conflicts of interest to disclose.

I have been privileged to be editor-in-chief of Eye & Contact Lens for the past 6 years and have led an audacious team to provide quality evidence-based information on contact lenses and a wide variety of topics related to cornea, anterior segment disease, and surgery that have direct relevance to clinical care worldwide.

We have sponsored five ECL symposia that have resulted in five themed issues and another in preparation to provide key information to a worldwide audience:

  • (1) Keratoconus and UV Corneal Cross-linking, June 2014, Toronto, Canada; Eye & Contact Lens: Science & Clinical Practice. 40(6):325, November 2014.
  • (2) Myopia Epidemic and Myopia Progression, May 2015, Denver, CO; Eye & Contact Lens: Science & Clinical Practice. 42(1):1-2, January 2016.
  • (3) Contact Lens Discomfort, April 2016, Seattle, WA; Eye & Contact Lens: Science & Clinical Practice. 43(1):1, January 2017.
  • (4) 2 issues: Controlling Myopia Progression: November 2017, Joint Symposium between Myopia Society Japan and Eye & Contact Lens; Eye & Contact Lens: Science & Clinical Practice. 44(4) 203, July 2018; https://journals.lww.com/claojournal/toc/2018/07000.

Eye & Contact Lens: Science & Clinical Practice. 44(5) 273, Sept 2018; https://journals.lww.com/claojournal/toc/2018/09000.

  • (5) Biomarkers for Ocular Surface Disease, April 2019, Vancouver, Canada (themed issue in preparation).

We are grateful for the educational grants that have enabled us to organize these symposia (listed in alphabetical order): Alcon, Ametek, Art Optical Contact Lens, Avedro, Inc., AYOXXA, Bausch & Lomb, Contamac, Kala, Medmont, Menicon, Novaliq, Oasis Medical (formerly Addition Technology), Ocular Therapeutix, Oculus, Paragon Vision Sciences, Inc., Reichert Technologies, Santen, Shire, and Sun.

The FDA has published in ECL up-to-date information on issues that concern drug/device developers and the clinician scientists looking to meet unmet medical needs with innovative products, while reducing risks for device usage:

We are committed to publishing original research, reviews of key topics, and case reports. It would be difficult to cite all the great articles included in recent years that have contributed useful information for a worldwide audience. We owe thanks to all the authors who worked so hard to provide pivotal information for all of us.

Despite the growing number of opportunities for publishing, including open access journals, ECL has continued to receive quality submissions that address readers' needs for up-to-date information. I sincerely thank the hard and continuous efforts of our associate editors, ECL board of editors, all reviewers, ECLA board of directors, our publisher LWW, and our managing editors, Steve Cohen and Terry Monahan, who have enabled ECL to revamp editorial processes to provide rapid review of submissions and quick online publication of accepted articles.

I pass the baton to the next editor-in-chief, Bennie Jeng, MD, with full confidence in his abilities to go forward with ECL with the continued support of the ECLA board of directors.

Thank you everyone.

© 2019 Contact Lens Association of Ophthalmologists, Inc.